Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma

The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM. HUHS1015 ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Yoshiko, Nagaya, Hisao, Tsuchiya, Ayako, Kanno, Takeshi, Gotoh, Akinobu, Tanaka, Akito, Shimizu, Tadashi, Nakao, Syuhei, Tabata, Chiharu, Nakano, Takashi, Nishizaki, Tomoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317914/
https://www.ncbi.nlm.nih.gov/pubmed/24754309
http://dx.doi.org/10.1111/cas.12429
Descripción
Sumario:The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM. HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells. HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis. HUHS1015 clearly suppressed tumor growth in mice inoculated with NCI-H2052 cells. Taken together, the results of the present study indicate that HUHS1015 could be developed as an effective anticancer drug for treatment of malignant pleural mesothelioma.

Ejemplares similares